Nephrology

The Biology and Genetics of Alport Syndrome

At a Glance

Alport syndrome is caused by genetic mutations that prevent the kidneys from building strong Type IV collagen. This structural weakness damages the kidney filters over time. The disease severity depends heavily on which specific gene is affected and how the mutation was inherited.

To understand Alport syndrome, it helps to think of the kidneys as a house. The filters in the kidneys, called glomeruli, rely on a specific type of “rebar” or steel reinforcement to hold their structure. This reinforcement is made of Type IV Collagen ^[1]. When this collagen is built correctly, the filters work perfectly. In Alport syndrome, a genetic “glitch” means the rebar is either missing or poorly made, causing the filters to gradually weaken and fail ^[2]^[3].

The Three-Chain Network

The collagen used in kidney filters is unique because it is made of three specific protein chains: α3 (alpha-3), α4 (alpha-4), and α5 (alpha-5) ^[4]. These three chains must twist together like a sturdy rope to form a functional network ^[5].

COL4A5 is the gene that provides instructions for the α5 chain.
COL4A3 and COL4A4 provide instructions for the α3 and α4 chains.

If any one of these three genes has a mutation, the “rope” cannot form properly. Instead, the kidney tries to use a weaker, “emergency” version of collagen (made of the alpha-1-1-2 network of chains), but this substitute is not strong enough to withstand the pressure of filtering blood ^[6]^[7].

Main Genetic Subtypes

How Alport syndrome progresses depends heavily on which gene is affected and how the mutation was passed down (inheritance pattern).

Subtype	Gene(s) Involved	Inheritance	General Progression
XLAS (X-Linked)	COL4A5	From the X chromosome	Most common (80%). Affects males more severely than females ^[8].
ARAS (Autosomal Recessive)	COL4A3 or COL4A4	Two mutations (one from each parent)	Often the fastest progression; kidney failure usually occurs in early adulthood ^[9]^[10].
ADAS (Autosomal Dominant)	COL4A3 or COL4A4	One mutation (from one parent)	Typically the mildest form; progression is slower and highly variable ^[11]^[12].
Digenic	Two genes (e.g., COL4A3 + COL4A4)	Mutations in two different genes	Usually more severe than the dominant (ADAS) form but potentially slower than the recessive (ARAS) form ^[13]^[14].

Why “Type” Matters: Truncating vs. Non-Truncating

Not all mutations are equal. Your genetic report might mention the “type” of mutation, which helps predict the disease’s severity (called genotype-phenotype correlation).

Truncating Mutations: These act like a “stop” sign in the middle of a sentence. They cause the body to stop building the collagen chain early, leaving it incomplete and often non-functional ^[15].
Non-Truncating (Missense) Mutations: These are like a “typo” in a sentence—one letter is swapped for another. While the collagen chain is finished, it may be misshapen. Interestingly, some missense mutations can be just as severe as truncating ones because they “poison” the rest of the collagen network ^[16]^[17].

Males vs. Females in XLAS

The most common form, X-Linked Alport Syndrome (XLAS), affects males and females differently due to how our chromosomes work:

Males: Since they have only one X chromosome, a mutation in the COL4A5 gene means they have no healthy “backup” ^[18]. Most males with XLAS will experience kidney decline by their 20s or 30s without treatment ^[19].
Females: Because they have two X chromosomes, they usually have one healthy copy of the gene to help out. This was historically called being a “carrier,” but doctors now know that females with XLAS can develop serious kidney issues ^[8]. Their progression is typically much slower than males, but they still require lifelong monitoring ^[18]. Increasing proteinuria (protein in the urine) is often the first sign that the kidneys need extra support ^[8].

Common questions in this guide

What is the main cause of Alport syndrome?

Alport syndrome is caused by genetic mutations in the COL4A3, COL4A4, or COL4A5 genes. These mutations prevent the kidneys from building a specific type of structural protein called Type IV collagen, causing the kidney filters to weaken and fail over time.

What is X-linked Alport syndrome (XLAS)?

XLAS is the most common form of Alport syndrome, passed down on the X chromosome. It typically affects males more severely because they only have one X chromosome, while females have a second X chromosome that often slows the progression of the disease.

Can females with X-linked Alport syndrome develop kidney issues?

Yes, females with XLAS can develop serious kidney problems, though the progression is usually slower than in males. Increasing protein in the urine is often the first sign that their kidneys need extra medical support and lifelong monitoring is required.

What is the difference between a truncating and non-truncating mutation?

A truncating mutation stops the body from fully building the collagen chain, leaving it incomplete and non-functional. A non-truncating mutation finishes the chain but includes an error, which can still cause significant problems by making the collagen misshapen.

Who in my family should be screened for Alport syndrome?

Because Alport syndrome is inherited, relatives should consider being screened if they have a family history of kidney issues, unexplained blood or protein in the urine, hearing loss, or vision changes.

Curated prompts to bring to your next appointment.

1.Was my (or my child's) mutation 'truncating' or 'non-truncating,' and what does that mean for our timeline?
2.If my daughter has XLAS, how does 'X-inactivation' affect her risk compared to a male family member?
3.Does our genetic report show a single mutation (monogenic) or mutations in two different genes (digenic)?
4.Given the inheritance pattern, which family members should be screened for hematuria or offered genetic testing?

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References (19)

1
A chloride ring is an ancient evolutionary innovation mediating the assembly of the collagen IV scaffold of basement membranes.
Pedchenko V, Bauer R, Pokidysheva EN, et al.
The Journal of biological chemistry 2019; (294(20)):7968-7981 doi:10.1074/jbc.RA119.007426.
PMID: 30923125
2
Trimerization profile of type IV collagen COL4A5 exon deletion in X-linked Alport syndrome.
Koyama Y, Suico MA, Owaki A, et al.
Clinical and experimental nephrology 2024; (28(9)):874-881 doi:10.1007/s10157-024-02503-9.
PMID: 38658441
3
An overview of the multi-pronged approach in the diagnosis of Alport syndrome for 22 children in Northeast China.
Zhang L, Sun BC, Zhao BG, Ma QS
BMC nephrology 2020; (21(1)):294 doi:10.1186/s12882-020-01962-y.
PMID: 32703181
4
Accumulation of worn-out GBM material substantially contributes to mesangial matrix expansion in diabetic nephropathy.
Kriz W, Löwen J, Federico G, et al.
American journal of physiology. Renal physiology 2017; (312(6)):F1101-F1111 doi:10.1152/ajprenal.00020.2017.
PMID: 28228399
5
Collagen IV of basement membranes: III. Chloride pressure is a primordial innovation that drives and maintains the assembly of scaffolds.
Boudko SP, , Pedchenko VK, et al.
The Journal of biological chemistry 2023; (299(11)):105318 doi:10.1016/j.jbc.2023.105318.
PMID: 37797699
6
Bidirectional, non-necrotizing glomerular crescents are the critical pathology in X-linked Alport syndrome mouse model harboring nonsense mutation of human COL4A5.
Song JY, Saga N, Kawanishi K, et al.
Scientific reports 2020; (10(1)):18891 doi:10.1038/s41598-020-76068-4.
PMID: 33144651
7
Lysyl Oxidase-like-2 Cross-links Collagen IV of Glomerular Basement Membrane.
Añazco C, López-Jiménez AJ, Rafi M, et al.
The Journal of biological chemistry 2016; (291(50)):25999-26012 doi:10.1074/jbc.M116.738856.
PMID: 27770022
8
A Systematic Review of Pathogenic COL4A5 Variants and Proteinuria in Women and Girls With X-linked Alport Syndrome.
Gibson JT, de Gooyer M, Huang M, Savige J
Kidney international reports 2022; (7(11)):2454-2461 doi:10.1016/j.ekir.2022.08.021.
PMID: 36531881
9
Clinical, histological and molecular characteristics of Alport syndrome in Chinese children.
Zhou L, Xi B, Xu Y, et al.
Journal of nephrology 2023; (36(5)):1415-1423 doi:10.1007/s40620-023-01570-7.
PMID: 37097554
10
Features of Autosomal Recessive Alport Syndrome: A Systematic Review.
Lee JM, Nozu K, Choi DE, et al.
Journal of clinical medicine 2019; (8(2)) doi:10.3390/jcm8020178.
PMID: 30717457
11
Slowly progressive autosomal dominant Alport Syndrome due to COL4A3 splicing variant.
Daga S, Loberti L, Rollo G, et al.
European journal of human genetics : EJHG 2025; (33(4)):461-467 doi:10.1038/s41431-024-01706-8.
PMID: 39424670
12
Glomerular Basement Membrane Protein Expression and the Diagnosis and Prognosis of Autosomal Dominant Alport Syndrome.
Akihisa T, Sato M, Wakayama Y, et al.
Kidney medicine 2019; (1(6)):391-396 doi:10.1016/j.xkme.2019.06.007.
PMID: 32734219
13
Digenic Alport Syndrome.
Savige J, Renieri A, Ars E, et al.
Clinical journal of the American Society of Nephrology : CJASN 2022; (17(11)):1697-1706 doi:10.2215/CJN.03120322.
PMID: 35675912
14
Clinical, Pathological, and Genetic Characteristics of Patients with Digenic Alport Syndrome.
Inoki Y, Horinouchi T, Yamamura T, et al.
Kidney360 2024; (5(10)):1510-1517 doi:10.34067/KID.0000000000000547.
PMID: 39137047
15
Angiotensin-converting enzyme inhibitors in patients with Alport syndrome: can all patients benefit?
Rheault MN
Kidney international 2020; (98(6)):1400-1402 doi:10.1016/j.kint.2020.07.011.
PMID: 33276866
16
Is there a dominant-negative effect in individuals with heterozygous disease-causing variants in COL4A3/COL4A4?
Riedhammer KM, Simmendinger H, Tasic V, et al.
Clinical genetics 2024; (105(4)):406-414 doi:10.1111/cge.14471.
PMID: 38214412
17
Lack of collagen α6(IV) chain in mice does not cause severe-to-profound hearing loss or cochlear malformation, a distinct phenotype from nonsyndromic hearing loss with COL4A6 missense mutation.
Tang S, Yonezawa T, Maeda Y, et al.
PloS one 2021; (16(4)):e0249909 doi:10.1371/journal.pone.0249909.
PMID: 33848312
18
Clinical practice recommendations for the diagnosis and management of Alport syndrome in children, adolescents, and young adults-an update for 2020.
Kashtan CE, Gross O
Pediatric nephrology (Berlin, Germany) 2021; (36(3)):711-719 doi:10.1007/s00467-020-04819-6.
PMID: 33159213
19
Genotype-Phenotype Correlations for Pathogenic COL4A3-COL4A5 Variants in X-Linked, Autosomal Recessive, and Autosomal Dominant Alport Syndrome.
Savige J, Huang M, Croos Dabrera MS, et al.
Frontiers in medicine 2022; (9()):865034 doi:10.3389/fmed.2022.865034.
PMID: 35602506

This page explains the genetics and biology of Alport syndrome for educational purposes. Always consult a genetic counselor or nephrologist to interpret your specific genetic testing results.

Get notified when new evidence is published on Alport syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Guide Contents